Royal Bank of Canada Issues Positive Forecast for Prestige Consumer Healthcare (NYSE:PBH) Stock Price

Prestige Consumer Healthcare (NYSE:PBH) had its price objective hoisted by Royal Bank of Canada from $96.00 to $97.00 in a research report report published on Friday,Benzinga reports. The brokerage currently has a sector perform rating on the stock.

A number of other equities analysts have also recently commented on the stock. Oppenheimer boosted their price target on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an “outperform” rating in a research note on Thursday, February 13th. Sidoti cut shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price target for the company. in a research note on Monday, December 9th. DA Davidson boosted their price target on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a “buy” rating in a research note on Friday, February 7th. Canaccord Genuity Group boosted their price target on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, February 7th. Finally, Raymond James raised shares of Prestige Consumer Healthcare to a “moderate buy” rating in a research note on Thursday, December 19th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $93.33.

Prestige Consumer Healthcare Stock Performance

Prestige Consumer Healthcare stock opened at $84.12 on Friday. The firm’s 50 day simple moving average is $82.46 and its 200 day simple moving average is $78.64. The company has a current ratio of 3.68, a quick ratio of 2.20 and a debt-to-equity ratio of 0.56. The firm has a market capitalization of $4.17 billion, a PE ratio of 19.70, a price-to-earnings-growth ratio of 2.69 and a beta of 0.46. Prestige Consumer Healthcare has a 1-year low of $62.35 and a 1-year high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Thursday, February 6th. The company reported $1.22 earnings per share for the quarter, topping analysts’ consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. As a group, analysts expect that Prestige Consumer Healthcare will post 4.5 earnings per share for the current fiscal year.

Insider Activity

In other Prestige Consumer Healthcare news, SVP Mary Beth Fritz sold 1,678 shares of the stock in a transaction on Monday, March 10th. The shares were sold at an average price of $90.00, for a total transaction of $151,020.00. Following the completion of the sale, the senior vice president now owns 17,157 shares of the company’s stock, valued at $1,544,130. This represents a 8.91 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 1.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Institutional investors have recently added to or reduced their stakes in the company. Kestra Investment Management LLC purchased a new stake in Prestige Consumer Healthcare during the 4th quarter valued at $27,000. CIBC Private Wealth Group LLC boosted its position in Prestige Consumer Healthcare by 48.9% during the 4th quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company’s stock valued at $34,000 after buying an additional 152 shares during the period. Headlands Technologies LLC purchased a new stake in Prestige Consumer Healthcare during the 4th quarter valued at $40,000. McIlrath & Eck LLC boosted its position in Prestige Consumer Healthcare by 19.1% during the 4th quarter. McIlrath & Eck LLC now owns 959 shares of the company’s stock valued at $75,000 after buying an additional 154 shares during the period. Finally, Johnson Financial Group Inc. purchased a new stake in Prestige Consumer Healthcare during the 4th quarter valued at $93,000. Hedge funds and other institutional investors own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.